Sun Pharma, Novartis Settle Suit Involving Gleevec Leukemia Drug
This article was originally published in PharmAsia News
Executive Summary
Sun Pharmaceutical Industries and Novartis settled a lawsuit over Sun's generic of Glivec/Gleevec (imitinib) leukemia drug by allowing the India-based firm to launch its version in the U.S. as of Feb.1, 2016.